Results 201 to 210 of about 589,562 (349)

New approaches to treating chronic obstructive pulmonary disease with Colla corii asini

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Colla corii asini improves chronic obstructive pulmonary disease (COPD) treatment through anti‐inflammatory, antioxidant, immune‐modulatory, and lung‐nourishing effects, addressing current therapeutic challenges via multitarget mechanisms. Abstract Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and disability ...
Wenchao Zhang   +5 more
wiley   +1 more source

Chemical Synthesis of Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii Capsular Polysaccharide Fragments as Leads for Cross‐Protection

open access: yesAngewandte Chemie, EarlyView.
A total of 16 chemically synthesized capsular polysaccharide (CPS) fragments related to Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii were analyzed by glycan microarray. Comparative screening revealed three conserved epitopes that act as cross‐protective vaccine lead candidates against multidrug‐resistant (MDR) bacterial ...
Amar Kumar Mishra   +9 more
wiley   +2 more sources

Polydatin alleviates mitochondrial damage and apoptosis of lung epithelial cells by inhibiting toll‐like receptor 4‐dependent macrophage activation in asthma

open access: yesAnimal Models and Experimental Medicine, EarlyView.
The alleviation of asthma by polydatin is dependent on the blockage of the toll‐like receptor 4 (TLR4)/P2X7R synergy in macrophages. The blockage of the TLR4/P2X7R synergy results in decreased release and secretion of interleukin‐1β (IL‐1β) and IL‐18. In epithelial cells, low IL‐1β and IL‐18 levels inhibit mitochondrial damage and apoptosis.
Guangxing Li   +9 more
wiley   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy